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Abstract
Hepatitis C virus (HCV) is efficient in the establishment of persistent infection. We have previously shown that HCV core protein inhibits
T cell proliferation through its interaction with the complement receptor, gC1qR. Here we show that HCV core-induced inhibition of T cell
proliferation involves a G0/G1 cell cycle arrest, which is reversible upon addition of anti-gC1qR antibody. Correspondingly, the expression
of cyclin-dependent kinases (Cdk) 2/4 and cyclin E/D, as well as subsequent phosphorylation of retinoblastoma (pRb), is reduced in
core-treated T cells in response to mitogenic stimulation. Remarkably, degradation of p27Kip1, a negative regulator of both Cdk4/cyclin D
and Cdk2/cyclin E complexes, is significantly diminished in T cells treated with HCV core upon mitogenic stimulation. These data indicate
that the stability of p27Kip1 by HCV core is associated with blocking activated T cells for the G1 to S phase transition and inhibiting T cell
proliferation.
© 2003 Elsevier Inc. All rights reserved.
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Introduction
Hepatitis C virus (HCV) is a serious and growing threat
to human health, having infected approximately 170 million
people worldwide (Houghton, 1996). HCV causes a spec-
trum of liver diseases, ranging from an asymptomatic carrier
state to end-stage diseases. Remarkably, the majority of
individuals with HCV fail to resolve the infection and
progress to a chronic state. Persistent HCV infection is
associated with liver cirrhosis and hepatocellular carci-
noma, thus becoming a leading cause of liver transplanta-
tion in the United States (Houghton, 1996). Unfortunately,
no vaccine or effective treatment for HCV is currently
available, and the mechanism(s) leading to HCV chronicity
is not well defined.
Similar to many persistent DNA viruses, HCV, a single-
stranded RNA virus, has evolved one or more mechanisms
to establish and maintain viral persistent infection. Promi-
nent features of HCV are its apparent immune evasion and
quasispecies nature. Although a high rate of genetic vari-
ability may facilitate viral escape and persistence in the face
of anti-viral specific immunity (Afonso et al., 1999), im-
mune responses to HCV, both cellular and humoral, are not
sufficient to resolve infection in most humans or protect
against reinfection in chimpanzees (Farci et al., 1992; Alter,
1997). In addition, several studies provide compelling evi-
dence that HCV is associated with opportunistic infections.
This is well supported by increased susceptibility of chronic
HCV patients to other microbial pathogens, including vi-
ruses (Liaw, 1995; Jardi et al., 2001), bacteria (Wu et al.,
1995; Pellicano et al., 2000; Zucca et al. 2000; Spinzi et al.,
2001), and parasites (Mohamed et al., 1998; Blanton et al.,
2002). During HCV infection, anti-viral immune response is
severely impaired. IgG1 restriction, low titer, and a delayed
appearance of antibody response are observed (Ray and
Ray, 2001). Strong and broad CTL and Th1 responses have
been detected in individuals with acute hepatitis C, who
subsequently clear the virus; however, these T cell re-
sponses are not sustained (Lechner et al., 2000a, 2000b). In
* Corresponding author. Fax: 1-434-924-1221.
E-mail address: ysh5e@virginia.edu (Y.S. Hahn).
R
Available online at www.sciencedirect.com
Virology 314 (2003) 271–282 www.elsevier.com/locate/yviro
0042-6822/03/$ – see front matter © 2003 Elsevier Inc. All rights reserved.
doi:10.1016/S0042-6822(03)00419-7
patients chronically infected with HCV, the frequencies of
antiviral CTL are relatively low (Rehermann et al., 1996)
and the proliferative response of HCV-specific CD8 T
cells was impaired (Wedemeyer et al., 2002). In addition,
the production of Th1-type cytokines (i.e., IL-2 and IFN-)
is dramatically suppressed in peripheral T cells of chronic
HCV patients (Tsai et al., 1997; Lechmann et al., 1999).
These observations suggest that HCV chronic infection
may, at least in part, be the result of an inability to mount
effective T lymphocyte responses, indicating that HCV
gene product(s) might be involved in modulating or sup-
pressing host immune responses. HCV core protein is the
first protein to be synthesized during the early phases of
HCV infection and core protein (genotype 1a) plays a role
in impairing the host immune response to viral infection
(Ray and Ray, 2001; Yao et al., 2001b).
HCV core protein is viral nucleocapsid protein with
multiple functions (Ray and Ray, 2001). The presence of a
putative DNA-binding motif, nuclear localization signals,
and phosphorylation sites on core protein suggests its pos-
sible function as a gene regulator. These intriguing proper-
ties suggest that core protein, in concert with its cellular
partners, may contribute to pathogenesis during persistent
HCV infection. Recently, it has been reported that free core
particles are found circulating in the bloodstream of HCV-
infected patients, suggesting an immunopathological role in
disease progression (Masalova et al., 1998; Maillard et al.,
2001). Detection of core antigen in patient’s serum or
plasma serves as a marker of HCV viremia in the serolog-
ical (antibody negative) window phase (Peterson et al.,
2000; Widell et al., 2002). Intriguingly, extracellular core
protein is able to dampen the host immune response (Large
et al., 1999; Yao et al., 2001a; Lee et al., 2001). The
molecular basis of suppressing host immune response by
extracellular core protein is mediated by its interaction with
the complement receptor, gC1qR (Kittlesen et al., 2000).
However, the precise mechanism(s) of core-induced immu-
nosuppression remains to be identified.
An essential feature of the cellular immune response is
the activation of T lymphocytes through TCR engagement
by HLA-associated antigens. Ligation of TCR/CD3 pro-
vides an activation signal involving the induction of a num-
ber of genes, including the cytokine IL-2. The binding of
IL-2 to its receptor is essential for TCR-stimulated cell
cycle progression from G1 to S phase. Cell cycle progres-
sion is regulated by the coordinated expression and post-
translational modification of cyclin-dependent kinases
(Cdk) and their regulatory partners, cyclins. Specific kinase
complexes, including cyclin D–Cdk4/6 and cyclin E–Cdk2,
regulate the G1 to S transition by phosphorylating sub-
strates, such as the pocket protein retinoblastoma (pRb).
Additionally, two families of Cdk inhibitors (CKI), Cip/Kip
and Ink4, have been identified (Sherr and Robert, 1995).
The Cip/Kip members, including p21Cip, p27Kip1, and
p57Kip2, associate with both cyclin E and D complexes,
whereas the Ink4 members, including p15Ink4b, p16Ink4a,
p18Ink4c, and p19Ink4d, inhibit cyclin D–Cdk4/6 complex
formation (Sherr and Robert, 1995). Together, these inhib-
itors are critical regulators of the G1 to S transition.
During HCV infection, only a minor fraction of periph-
eral blood mononuclear cells (PBMC) is actually infected in
vivo. Therefore, indirect mechanisms, such as contact be-
tween infected and uninfected cells or, more likely, inter-
action of soluble core protein, circulating in the blood of
patients (Masalova et al., 1998; Maillard et al., 2001), with
surface molecules on uninfected cells, may play an impor-
tant role in dampening host immune response. Previously,
we have demonstrated that HCV core impairs the activation
of mitogen-activated protein kinase (MAPK) through an
interaction with the globular C1q receptor, gC1qR (Yao et
al., 2001a). This suggests that the interaction between HCV
core and gC1qR may interfere with the early event of T cell
activation. The importance of cell cycle regulatory proteins
in T cell proliferation prompted us to examine whether these
proteins might be targets for modulation by HCV core and
thus contribute to the mechanism(s) of core-induced T cell
unresponsiveness. We have therefore analyzed the effects of
core protein on cell cycle progression, expression of essen-
tial components of G1 Cdk–cyclin complexes, and Cdk
inhibitors in human PBMC in response to either anti-CD3/
CD28 or Con A stimulation. We found that HCV core-
induced inhibition of T lymphocyte proliferation was asso-
ciated with retardation of cell cycle progression from G1 to
S phase by stabilization of p27Kip1, an inhibitor of cell cycle
regulatory proteins.
Results
HCV core inhibits cell cycle progression in human T cells
in response to mitogenic stimulation
We have previously demonstrated that HCV core inhibits
T cell activation and proliferation through an interaction
with gC1qR (Kittlesen et al., 2000; Yao et al., 2001a). To
further determine the underlying mechanism for HCV core/
gC1qR-induced inhibition of T cell function, we examined
the effect of HCV core on cell cycle progression of T cells
in response to mitogenic stimulation. Purified peripheral
blood monocytes from healthy blood donors were treated
with recombinant 6H-core or 6H-DHFR as a control and
were stimulated with either Con A (Fig. 1 A, B, and C) or
anti-CD3/CD28 (Fig. 1D, E, and F). Cells were harvested at
various time points after TCR stimulation and DNA content
was measured by propidium iodide (PI) staining, followed
by flow cytometry analysis.
As shown in Fig. 1A and D, upon 1 day of mitogenic
stimulation, 2–3% of activated T cells had entered S 
G2/M phase from the quiescencent G0/G1 stage, and no
significant difference in DNA content was observed for
HCV core- or DHFR-treated cells. The degree of cell
cycle progression in DHFR-treated cells was similar to
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that in mitogen-stimulated cells, suggesting that DHFR
does not interfere with the cell cycle progression of T
cells (data not shown). By day 3 of stimulation, DHFR-
treated cells exhibited an increase in S phase progression,
while an inhibition of S phase entry was observed in
core-treated cells. After 5 days of stimulation, 12–13% of
DHFR-treated cells were shown to be in S phase (Fig. 1C
and F), while only 3–5% of those treated with core
protein had progressed to S phase (Fig. 1B and E). This
result suggests that HCV core arrests the cell cycle pro-
gression of activated T cells in G0/G1 and inhibits entry
of these cells into S phase.
HCV core/gC1qR interaction is directly involved in
inhibition of cell cycle progression of activated T cells
To determine whether HCV core-induced cell cycle ar-
rest of activated T lymphocytes is mediated directly by its
interaction with gC1qR, we examined the effect of anti-
gC1qR antibody on abrogation of core-induced cell cycle
arrest. To this end, HCV core-treated PBMC were stimu-
lated with anti-CD3/CD28 Abs in the presence of anti-
gC1qR Ab or control serum, and cell cycle progression was
examined on day 5 by PI staining. As shown in Fig. 2A,
12.7% of anti-CD3/CD28-stimulated cells progressed into
S/G2 phase, while only 4.6% of activated cells entered S/G2
phase in the presence of core protein. Importantly, 10.4% of
core-treated cells progressed to S/G2 in the presence of
anti-gC1qR Ab, suggesting that this antibody is able to
partially reverse the inhibitory effect of HCV core on T cell
cycle progression, while prebleed serum failed to reverse
the core-induced inhibition of T cell cycle progression.
To confirm the core’s inhibitory effect on T cell cycle
progression by the core/gC1qR interaction, we examined
the cell cycle progression by staining PBMC with both
CFDA-SE and APC-conjugated anti-CD3 Ab. CFDA-SE
(CFSE) labels live cells and segregates equally between
daughter cells during mitosis. Thus, the flow cytometry
analysis of CFSE-labeled cells is a sensitive method to
quantify the cell cycle progression. To this end, PBMC were
labeled with CFSE and treated with HCV core or DHFR
followed by stimulation with Con A. We also examined the
cell cycle progression of core-treated cells in the presence of
anti-gC1qR antibody or a control antibody. At various time
points following the treatment, the cells were stained with
APC-anti-CD3, and the cell cycle progression of activated T
cells was analyzed by assessing the fluorescence intensity of
CFSE-labeled CD3 T cells.
As shown in Fig. 2B, upon 4 h of stimulation in both
core-treated cells and untreated cells, 58% of T cells were
detected in M2 (higher intensity of CFSE staining), while
42% of T cells were detected in M1 gate (lower intensity
Fig. 1. HCV core inhibits the cell cycle progression of activated T cells from G1 to S phase. Human PBMC were treated with HCV core (2 g/ml) or DHFR
(2 g/ml) as a control followed by TCR stimulation with either Con A (A, B, C) or anti-CD3/CD28 (D, E, F). The percentage of activated T cells in S
G2 phase, as represented by DNA content, after 1, 3, and 5 days of mitogenic stimulation is shown in A and D. The DNA content of the lymphocyte population
at day 5 after core or DHFR treatment is represented by histograms (B, C, E, F). These results were reproducible in three independent experiments.
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of CFSE staining). Upon 1 day of mitogenic stimulation
in untreated cells, 50% (91% at day 1 minus 42% at 4 h)
of T cells had progressed from M2 to M1, which indi-
cated the cell division, and 9% of the cells still remained
in the M2 gate. In contrast, diminished cell cycle pro-
gression was observed for HCV core-treated cells upon
mitogenic stimulation. Only 25% (67% at day 1 minus
42% at 4 h) of core-treated cells progressed from M2 to
M1 upon mitogenic stimulation, while 30% of the cells
remained in M2. In addition, the inhibition of cell cycle
progression by HCV core was shown in cells following 3
or 5 days of stimulation (data not shown). Furthermore,
the addition of anti-gC1qR antibody to core-treated cul-
ture restored the core-induced inhibition of cell cycle
progression, confirming that gC1qR is involved in HCV
core-induced cell cycle arrest.
HCV core inhibits activation-associated Cdk/cyclin
complex formation
Cell cycle progression is driven by the sequential acti-
vation of Cdks and their regulatory partners, cyclins. As
shown in Fig. 3A , activation of Cdk4/Cdk6 complexed with
D-type cyclins in mid G1 phase and Cdk2–cyclin E late in
G1, is particularly important for passing the G1/S restriction
point. To investigate the effect of HCV core on regulation of
Cdk/cyclin expression, we analyzed the expression levels of
the G1/S Cdks and cyclins following stimulation with anti-
CD3/CD28, in the presence of core or DHFR, by Western
blot analysis. As shown in Fig. 3B, quisescent cells did not
express detectable levels of Cdk2/Cdk4, while the expres-
sion of Cdk2/4 was detectable at 48 and 72 h after mitogenic
stimulation.
Fig. 2. Anti-gC1qR antibody abrogates HCV core-induced inhibition of T cell cycle progression. (A) The percentage of activated T cells entered into S/G2
phase. PBMC were cultured in the presence or absence of HCV core (2 g/ml) followed by stimulation with anti-CD3/CD28. Anti-gC1qR antibody or a
control serum was added to the culture to assess its ability to reverse inhibition of cell cycle progression by HCV core. After 5 days of treatment, the cell
cycle progression of activated T cells was analyzed by PI staining. (B) Analysis of cell cycle progression by CFSE staining. PBMC were labeled with CFSE
and were treated with HCV core or DHFR in the presence of anti-gC1qR antibody or a control serum. At various time points after Con A stimulation, the
cells were collected and stained with APC-anti-CD3 antibody to analyze the cell cycle progression of activated T cells. M1 and M2 indicates the percentage
of cells gated on low intensity of CFSE (dividing cells) and high intensity of CFSE (nondividing cells), respectively.
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Based on the time-dependent upregulation of Cdk2/4
expression, we next sought to examine the effect of core
protein on these regulators at 48 and 72 h after TCR stim-
ulation. As shown in Fig. 3C, HCV core inhibited the
activation-dependent upregulation of Cdk2 in T cells at 48
and 72 h after TCR stimulation, compared to control DHFR-
treated cells. The expression pattern of Cdk4 was found to
be very similar to that of Cdk2, except that the expression
level was lower than that of the former; thus, Cdk4 failed to
accumulate to a detectable level at 48 h, and only a very
faint band was detectable after 72 h of stimulation in the
presence of core protein (Fig. 3C). Correspondingly, the
levels of cyclin E and cyclin D expression, the catalytic
partners of the Cdk2 and Cdk4 in lymphocytes, were similar
to those of the Cdk subunits (Fig. 3C).
Since Cdk/cyclin activity is essential for passing the G1
restriction point and entering S phase, HCV core might
inhibit the activation-associated accumulation of Cdk/cyc-
lins, resulting in retardation of cell cycle progression. To
examine this possibility, we analyzed Cdk2/cyclin E activ-
ity in core-treated cells by measuring kinase activity in
vitro, using histone H1 as substrate. As shown in Fig. 3D,
Cdk2/cyclin E activity was observed by 48 h, with an
increase in substrate phosphorylation after 72 h of TCR
stimulation, for cell lysates derived from DHFR-treated
PBMC. However, for lysates obtained from cells treated
with HCV core, a significant downregulation of Cdk2 ki-
nase activity was observed at both 48 and 72 h after treat-
ment (Fig. 3D), suggesting that HCV core impairs activa-
tion of Cdk/cyclin kinase activity.
Cdk/cyclin-mediated phosphorylation of pRb, which
in turn activates a number of cell cycle regulatory pro-
teins, including E2F, is critical for cell division. As seen
in Fig. 4, cells stimulated with anti-CD3/CD28 in the
presence of DHFR revealed a distinct doublet, suggesting
that pRb is phosphorylated. In contrast, treatment of cells
Fig. 3. HCV core inhibits the expression of Cdk/cyclin proteins required for cell cycle progression from G1 to S phase. (A) Diagrammatic representation of
the cell cycle regulatory proteins. (B) Time-dependent expression of Cdk2 and Cdk4. PBMC were stimulated with anti-CD3/CD28 for various time points
(0, 24, 48, 72 h) and were analyzed for Cdk2 andCdk4 expression by Western blot analysis. (C) Expression of Cdk2,Cdk4 cyclin E, and cyclin D. Cells were
cultured in the presence of 2 g/ml of HCV core or DHFR for 48 or 72 h followed by anti-CD3/CD28 stimulation. Cell lysates were subjected to Western
blot analysis specific for Cdk2/4 and cyclin D/E. -Actin was employed as a loading control in these experiments. The data were reproducible in two
independent experiments. (D) Inhibition of Cdk2 in vitro kinase activity in core-treated PBMC. Equal amounts of cell lysates, derived from PBMC treated
as above, were used to immunoprecipitate Cdk2 complexes and subsequently tested for in vitro kinase activity to phosphorylate exogenous substrate, histone
H1. Phosphorylation of histone H1 was quantified and the mean OD  SD values are shown above. The results are reproducible in two independent
experiments.
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with HCV core resulted in a weak single band, suggesting
that core protein abolished the phosphorylation of pRb.
The expression level of a control protein, -actin, how-
ever, was not affected by core treatment. Taken together,
these results demonstrate that inhibition of S-phase entry
by HCV core is associated with the suppression of pro-
teins involved in cell cycle progression, such as Cdk/
cyclin complexes and pRb.
Cell cycle arrest by HCV core involves the Cdk inhibitor
p27Kip1
Two classes of inhibitors have been identified that neg-
atively regulate the kinase activity of G1-associated Cdks
(Sherr and Robert, 1995). One class, Ink4 (p15Ink4b,
p16Ink4a, p18Ink4c, and p19Ink4d), interferes with the forma-
tion of Cdk4/6–cyclin D complexes, while the other, Cip/
Kip (p21Cip, p27Kip1, and p57Kip2), has a more generalized
Cdk inhibitory activity. Among these, p27Kip1 has been
implicated as a central regulator of quiescence in T cells.
Downregulation of p27Kip1 in mitogen-stimulated T cells is
a primary event that is obligate for the activation of G1
kinase activity and subsequent S-phase entry, whereas over-
expression of p27Kip1 in T cells results in G1 arrest (Sherr
and Robert, 1995).
As shown in Fig. 5A , quiescent cells express high levels
of p27Kip1, correlating with the G0/G1 status of these cells.
Mitogenic stimulation of PBMC resulted in a rapid decline
in p27Kip1 expression over 48 h and the expression of
p27Kip1 was significantly diminished after 72 h stimulation.
In contrast, high levels of p27Kip1, but not -actin, was
found in core-treated cells compared to that in control cells
(Fig. 5B). Expression of the closely related Cip/Kip family
member, p21Cip, was rarely detectable at any time point in
our system (data not shown). We also determined expres-
sion levels of Ink4 family members, p15Ink4b and p16Ink4a,
which appeared to be unaffected by HCV core treatment
(data not shown).
HCV core affects p27Kip1 levels through its stabilization,
rather than Tob-mediated expression
Tob (transducer of erbB2), a negative regulator of acti-
vation that is related to a family of anti-proliferative pro-
teins, is highly expressed in anergic and quiescent T cells. It
was recently reported that the forced expression of Tob
inhibited T cell proliferation, cytokine production, and cell
cycle progression by promoting p27Kip1 transcription (Tza-
chanis et al., 2001). Therefore, it is possible that HCV core
may inhibit cell cycle progression by increasing the expres-
sion of p27Kip1 through Tob. To test this possibility, we
performed semiquantitive RT-PCR by serial dilution of RT
products (1:1, 1:5, 1:25, or 1:125) for Tob mRNA expres-
sion in cells treated with either 6H-core or 6H-DHFR. The
housekeeping gene, -actin, was employed as a RT-PCR
control in this experiment. As shown in Fig. 6A, Tob ex-
pression was unaffected by core treatment, when compared
with those treated with DHFR, for all RT dilutions. This
suggests that the high level of p27Kip1 in core-treated T cells
might be due to mechanisms other than Tob-mediated up-
regulation of p27Kip1 expression.
Since p27Kip1 was the only cell cycle inhibitor affected
by HCV core, and the accumulation of p27Kip1 in core-
treated cells was independent of Tob-mediated upregula-
tion, we further examined the mechanism of HCV core-
induced increased p27Kip1 levels in activated T cells by
assessing the stability of p27Kip1. A pulse–chase experiment
was performed to determine the rate of [35S] Met incorpo-
ration into p27Kip1, as well as the turnover rate of the
radiolabeled newly synthesized p27Kip1. To this end, cells
were first stimulated with Con A for 48 h since p27Kip1
begins to disappear 48 h after mitogenic stimulation of T
cells followed by labeling cells with [35S] Met in the pres-
ence of 6H-core, DHFR or medium for 6 h. [35S] Met-
Fig. 5. HCV core prevents the downregulation of p27Kip1 in activated T
cells. (A) Level of p27Kip1 in PBMC after anti-CD3/CD28 stimulation. Cell
lysates were prepared at various time points (0, 48, 72 h) after TCR
stimulation and p27Kip1 levels were determined by Western blot analysis.
(B) PBMC were incubated with either HCV core (2 g/ml) or DHFR (2
g/ml) followed by anti-CD3/CD28 stimulation. After 72-h stimulation,
the levels of p27Kip1 were assessed by Western blot analysis. -Actin was
employed as a loading control. These results were reproducible in three
independent experiments.
Fig. 4. HCV core inhibits pRb expression in mitogen-stimulated T cells.
PBMC were treated with either HCV core (2 g/ml) or DHFR (2
g/ml) and were stimulated with anti-CD3/CD28. After 48 and 72 h
stimulation, cell lysates from this culture were subjected to Western
blot analysis for pRb. -Actin was used as a loading control for this
experiment. The results of this experiment are reproducible in two
independent experiments.
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containing medium was then removed and the cells were
chased for 24 h. As shown in Fig. 6B, HCV core did not
affect the rate of p27Kip1 synthesis during the 6 h pulse
period. After the 24 h chase, the amount of radiolabeled
p27Kip1 was significantly reduced in cells treated with both
medium or DHFR (relative intensity nearly three times less
than that of HCV core), while it was not significantly af-
fected in the presence of core, suggesting that the newly
synthesized p27Kip1 in activated T cells was stabilized by
the treatment of core protein. Taken together, these data
indicate that HCV core affects the level of p27Kip1 in acti-
vated T cells through delayed degradation, rather than af-
fecting its rate of synthesis. Furthermore, the p27Kip1 stabi-
lization by addition of core protein into the culture on 2 days
after Con A stimulation suggests that HCV core is able to
inhibit the ongoing cell cycle progression after T cell acti-
vation.
Discussion
We have previously demonstrated that the HCV core/
gC1qR interaction inhibits T cell proliferation by interfering
with the ERK/MEK MAPK pathway (Kittlesen et al., 2000;
Yao et al., 2001a). In this study, we attempted to identify the
molecular events of HCV core-induced T cell unresponsive-
ness by determining cell cycle progression and the level of
cell cycle regulatory proteins in activated T cells. Our re-
sults demonstrated that HCV core arrests T lymphocytes in
G1 and blocks entry into S phase. In addition, anti-gC1qR
antibody treatment could reverse the core-induced inhibi-
tion of cell cycle progression, suggesting a direct role for the
HCV core/gC1qR interaction in the observed cell cycle
arrest. Importantly, p27Kip1, a crucial cell cycle inhibitor,
was found to be stabilized in HCV core-treated T cells.
Correspondingly, we observed a deregulation of Cdk2/4–
cyclinE/D complexes and pRb, both required for the G1 to
S transition, in the presence of HCV core protein.
The defect in cell cycle progression induced by HCV
core, described in this report, might explain the HCV core/
gC1qR-mediated anti-T cell proliferative effect previously
described (Kittlesen et al., 2000). It is important to point out
that C1q, the natural ligand of gC1qR, also suppresses T cell
proliferation by inhibiting cell cycle progression. Although
the molecular mechanism of cell cycle arrest by C1q/gC1qR
signaling has yet to be elucidated, upregulation of p27Kip1,
as was the case for core-treated cells, might be involved.
Based on our studies, we propose a model for the mecha-
nism of HCV core-induced cell cycle arrest. As shown in
Fig. 7, the HCV core/gC1qR interaction leads to inhibition
of activation-associated degradation of p27Kip1, which in
turn blocks Cdk/cyclin complex formation and pRb phos-
phorylation, thus blocking T cell cycle progression. How-
ever, the precise pathway(s) initially targeted by the core/
gC1qR interaction has yet to be fully elucidated.
Efficient ligation of the TCR by high-density antigen can
generate a productive T cell response characterized by cy-
tokine secretion and clonal expansion. In contrast, subopti-
mal cross-linking of the TCR by antigen alone, in the
absence of costimulation, is not sufficient to induce a pro-
ductive immune response, but instead leads to T cell anergy
(Schwardz, 1997). In contrast to primary unstimulated T
Fig. 6. HCV core affects p27kip1 levels through its stabilization, rather than
Tob-mediated expression. (A) HCV core- or DHFR-treated PBMC were
stimulated with anti-CD3/CD28 antibodies for 6 h. RNA isolated from
these cultures was used to synthesize Tob-specific cDNA with () or
without () RT. Using serial dilution (1:1, 1:5, 1:25, 1:125) of cDNA
template, Tob gene was amplified to compare the level of Tob gene
between core-treated cells and control cells. Amplification of -actin gene
from same samples was used as a control. Results are representative of
experiments conducted with PBMC from two different donors. (B) Effect
of HCV core on p27kip1 stability. PBMC were stimulated with Con A (2
g/ml) for 48 h and then pulsed with [35S]Met labeling medium containing
rIL-2 (100 U/ml) in the presence of medium alone, DHFR (2 g/ml), or
HCV core (2 g/ml) for 6 h. After removal of the radiolabeling medium,
cells were chased for 24 h in rIL-2-containing medium alone or that in the
presence of DHFR or HCV core. Radiolabeled newly synthesized p27kip1
was immunoprecipated and subjected to SDS–PAGE, followed by autora-
diography. The relative intensity of each band was measured by densitom-
etry and is shown at the bottom. These results were reproducible for two
independent experiments.
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cells, which can enter the cell cycle and clonally expand
after antigen-specific stimulation, anergic T cells do not
proliferate. Instead, they remain in a state of long-term
antigen-specific unresponsiveness. These events result in
increased expression of p27Kip1, defective Cdk/cyclin acti-
vation, inhibition of pRb phosphorylation, and blockade of
G1 to S phase progression (Boussiotis et al., 2000). p27Kip1
functions as an anergy factor and is an essential regulator
responsible for inhibiting of clonal expansion of anergic T
cells (Boussiotis et al., 2000). Under growth-arresting con-
ditions, p27Kip1 is translocated to Cdk2–cyclin E com-
plexes, inhibiting their activity (Polyak et al., 1994; Rey-
insdottir and Massague 1997). Upon activation of T cells,
especially by IL-2 mediated signaling, p27Kip1 is phosphor-
ylated and subsequently targeted for degradation in an ubiq-
uitin-dependent manner (Firpo et al., 1994; Nourse et al.,
1997). Interestingly, the kinases involved in this particular
phosphorylation step include the Cdk2–cyclin E complex
itself, for which p27Kip1 is both an inhibitor and a substrate
(Muller et al., 1997; Sheaff et al., 1997). In this report,
p27Kip1 degradation upon TCR stimulation was almost com-
pletely abolished in core-treated cells, as shown in Fig. 6B,
suggesting that HCV core might drive these cells into a state
of anergy. However, the molecular events required for
p27Kip1 stability, induced by the HCV core/gC1qR interac-
tion, have yet to be defined.
Several possibilities to explain such an effect are sum-
marized below. First, the inhibition of Cdk/cyclin complex
formation by HCV core may prevent phosphorylation and
degradation of p27Kip1, as described above (Muller et al.,
1997; Sheaff et al., 1997). Thus, the core-induced inhibition
of newly synthesized Cdk–cyclin complexes in mitogen-
stimulated T cells may not only affect downstream targets,
such as pRb, but also fail to trigger positive feedback mech-
anisms, which activate preexisting complexes through phos-
phorylation of p27Kip1 as shown in Figs. 5 and 6B. Second,
it has been shown that the activation of phosphatidylinositol
3-hydroxykinase (PI3K) target protein kinase (B) (PKB,
Akt) signaling pathway involves the activation-associated
down-regulation of p27Kip1 and T cells cycle progression
(Appleman et al., 2002). Thus, HCV core may disrupt the
activation of upstream kinases, such as PI3K/Akt (PKB),
necessary for p27Kip1 degradation (Avota et al., 2001;
Appleman et al., 2002). We are currently examining the
effect of HCV core on the alteration of PI3K/Akt activation.
Third, the observed deregulation of p27Kip1 is possibly due
to impaired ERK/MEK MAPK activation by HCV core, as
previously described (Yao et al., 2001a). As shown in Fig.
6B, HCV core stabilized p27Kip1 by 24 h, suggesting that
core’s effect is induced prior to this time point. Similarly,
HCV core inhibits activation of ERK/MEK MAPK by 24 h
(Yao et al., 2001a), suggesting that p27Kip1 stability may
occur independent of core-induced inhibition of MAPK.
Thus, it is likely that these two events may happen simul-
taneously as the result of HCV core treatment during early
T cell activation, although we do not exclude the possibility
that these two pathways may overlap by cross-talk to each
other. Last, following HCV core’s interaction with the
gC1qR and subsequent internalization (Yao et al., unpub-
lished data), core may form a complex with p27Kip1, thus
stabilizing it. Similarly, HCV core has been found to asso-
ciate with p21Cip1, also a CKI Cip/Kip family member, in
vitro (Wang et al., 2000). Our attempt to establish such an
interaction, by coimmunoprecipitation of HCV core with
p27Kip1, failed to detect such an association and, thus, also
excluded this possibility (data not shown). Nevertherless,
the delay in p27Kip1 degradation helps to explain our finding
that Cdk/cyclin complexes and pRb fail to accumulate in the
presence of HCV core, as shown in Fig. 7, thus preventing
progression of T cells from G1 to S phase.
Since cell cycle progression of activated T cells is a
multistep process in which many molecules must act in
concert, inactivation of one pathway could partially or com-
pletely abrogate the proliferative response (Taniguchi,
1995). Thus, a number of agents involved in suppressing T
cell proliferation have been reported to function through
several pathways. As is observed for cells arrested by HCV
core, IFN- appears to exert a potent antiproliferative signal
in several lymphoid cell lines via upregulation of the
p27Kip1, which dephosphorylates pocket proteins and leads
to G1 arrest (Erickson et al., 1999; Sangfelt et al., 1999). In
addition, IL-2-induced expression of both early and late G1
Cdk complexes, such as cyclin D–Cdk4 and cyclin E-Cdk2,
is also inhibited by IFN-. Similar to the biochemical events
Fig. 7. Model for inhibition of cell cycle arrest of activated T cells by HCV
core. The binding of HCV core on gC1qR displayed on the cell surface of
T cells will trigger gene(s) involved in p27kip1 expression and/or stability.
Thus, stable expression of p27kip1 in core-treated PBMC will lead to inhibit
the expression of proteins responsible for cell cycle progression from G1 to
S phase and arrest activated T cells at G1 phase.
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required for HCV core-mediated cell cycle arrest, rapamy-
cin involves in the blockade of IL-2-mediated p27Kip1 deg-
radation, leading to the suppression of T cell proliferation
(Nourse et al., 1994). However, the molecular mechanism
for the effect of other immunosuppressive agents, such as
undeculprodigiosin, differs from that induced by HCV core.
In undeculprodigiosin-treated cells, cell cycle arrest is me-
diated by blockade of cyclin E/A and Cdk2/4, without
alteration of p27Kip1 expression (Songia et al., 1997)
While examples of virus-induced G1 arrest are not very
numerous, they often include viruses known to suppress
lymphocyte function. Treatment with the V3 loop of an
HIV1 clone restricts the IL-2-dependent expression of
Cdk2-cyclin E activity in human T cells (Sakaida et al.,
1998). Additionally, measles-virus-induced immune sup-
pression has been found to be associated with deregulation
of G1 control proteins by disruption of Akt kinase activity
(Avota et al., 2001). Our data indicate that HCV core may
act further upstream than these immunosuppressive drugs
and viruses discussed above, as it exhibits a broader inhib-
itory effect on the cell cycle machinery.
HCV is characterized by a high incidence of persistent
infection, suggesting the evasion of immune surveillance by
this virus. Indeed, HCV core protein, one of HCV gene
products, contains the immunomodulatory function (Geis-
sler et al., 1998; Large et al., 1999; Ray and Ray, 2001).
There might be a genotype difference regarding core’s ef-
fect on suppressing host immune response, as suggested by
a recent study that the expression of core protein derived
from HCV genotype 1b in transgenic mice didn’t elicit such
an effect (Liu et al., 2002). Thus, studies on examining the
immunomodulatory function of different HCV genotypes
will be valuable in understanding HCV pathogenesis. In
addition, the quantity of core protein circulating in the
bloodstream of HCV-infected patients will be detrimental to
deliver the anti-T cell proliferative signal. Several studies
reported that nannomolar range of core protein is detectable
in the circulating blood of HCV-infected patients (Masalova
et al., 1998; Peterson et al., 2000; Maillard et al., 2001;
Widell et al., 2002). It is important to point out that this
concentration of core protein might be sufficient to inacti-
vate the function of immune cells in vivo. We are currently
investigating to determine the level of core protein during
the acute phase of viral infection and compare circulating
core level between patients who resolved infection and
patients who failed to clear the virus. Nevertheless, early
and sustained CD4 and CD8 T cell responses are crucial
for controlling HCV infection (Lechner et al., 2000a,
2000b). Therefore, the HCV core-mendiated inhibition of T
cell cycle progression, reported here, suggests that core
protein, circulating in the blood of patients upon infection,
may play a pivotal role in impairing intrahepatic, as well as
peripheral, T lymphocytes, thus facilitating the establish-
ment of persistent HCV infection. Further elucidation of
how HCV core protein modulates host immune responses to
infection may provide a basis for the rational design of
novel therapeutics.
Material and methods
PBMC isolation and culture
Human PBMC were isolated from peripheral blood of
donors (Virginia Blood Service, Richmond, VA) by Ficoll-
density centrifugation using lympholyte-H (Cedarlane Labs,
Ontario, Canada). PBMC were washed twice and incubated
with RPMI 1640 (Gibco BRL, Gaithersburg, MD) contain-
ing 10% (v/v) FBS (Hyclone), penicillin/streptomycin (100
g/ml, Gibco BRL, MD), L-glutamine (2 mM), and 2-ME
(5.5  105 M, Gibco BRL) at 37°C with 5% CO2 in a
humidified atmosphere for the following assays.
Antibodies and reagents
Recombinant 6H-core protein, with 6 histidine residues
tagged at the N-terminal of the full-length HCV core protein
(amino acid residue 2–191), was expressed and purified
under native condition. A control protein, 6H-DHFR, was
prepared in the same way as 6H-core protein. To activate
resting human PBMC, two different T cell mitogens were
employed: (1) Con A (2 g/ml, Sigma, St. Louis, O), (2)
anti-CD3 (UCHT-1, 1g/ml, PharMingen, San Diego, CA)
and anti-CD28 (1 g/ml, PharMingen). The following an-
tibodies specific for cell cycle regulatory proteins were
purchased from PharMingen for Western blot: p15Ink4b,
p16Ink4a, p21Cip, p27Kip1, Cdk2, Cdk4, cyclin E, cyclin D1/
D2/D3, and pRb. Rabbit anti--actin (Sigma) was used as a
loading control. Horseradish peroxidase (HRP)-anti-mouse
IgG and HRP-anti-rabbit IgG conjugates (Gibco BRL,
Gaithersburg, MD) served as secondary antibodies. gC1qR-
specific antibodies were obtained from rabbit by injecting
6H-gC1qR fusion protein. Histone H1 from Sigma and
[-32P] ATP were purchased from Amersham Pharmacia
Biotech (Arlington Heights, IL).
Cell cycle analysis by flow cytometry
A total of 2.5  105 PBMC were cultured with 200 l
RPMC medium in the presence of 2 g/ml of 6H-core or
6H-DHFR as a control protein and were stimulated with
either Con A (2 g/ml) or plate-bound anti-CD3/CD28
antibodies (1 g/ml). At days 1, 3, and 5 after treatment, the
cells were harvested in 1.5-ml Eppendorf tubes and washed
two times with PBS by centrifugation at 1000g for 5 min.
Cells were then resuspended in 400 l of propidium iodide
staining solution (50 g/ml propidium iodide, 0.1% sodium
citrate, 0.3% NP-40, 100 g/ml boiled RNase in 100 mM
NaAc, pH 5.0) and incubated at 4°C for 30 min. DNA
histograms and statistics were determined by FACS analysis
279Z.Q. Yao et al. / Virology 314 (2003) 271–282
using CellQuest software, based on collecting 10,000 events
of viable cells gated on lymphocyte populations.
To label PBMC with CFSE, 10  106 PBMC were
washed two times with PBS and then incubated with 5 M
CFSE in 10 ml of prewarmed PBS at 37°C in the dark for
8 min. The incorporation of CFSE into the living cells was
stopped by adding 30 ml RPMI 1640 containing 10% FBS.
Following centrifugation at 1200 RPM for 5 min, CFSE-
labeled PBMC were cultured in complete RPMI 1640 me-
dium stimulated with Con A (2 g/ml) and IL-2 (40 U/ml),
in the presence or absence of core protein (2 g/ml). Sub-
sequently, the cells were harvested at various time points,
washed with PBS, and then restained with APC-anti-CD3
conjugate (PharMingen) at room temperature in the dark for
1 h. The cells were washed and fixed with 1% paraformal-
dehyde in PBS prior to analysis of cell progression by
three-color flow cytometry (BD Bioscience, San Jose CA).
A total of 100,000 viable cells were collected and cell cycle
progression was analysed using CellQuest software gated
on the T lymphocyte population.
To examine whether blocking the core/gC1qR interac-
tion may abrogate the core’s inhibitory effect on cell pro-
gression, rabbit anti-gC1qR antibody (ELISA titer 1/12800)
was added simultaneously to the above culture at a 1:10
dilution. Prebleed serum from the same rabbit was used as
negative control. At various time points following treat-
ment, cells were harvested for staining, followed by cytom-
etry analysis.
Western blot analysis
A total of 2  106 PBMC were treated with 2 g/ml of
6H-core or 6H-DHFR for various intervals and activated
with anti-CD3/CD28 antibodies (1 g/ml). Cell lysates
were prepared by resuspending cell pellets in lysis buffer
(20 mM Tris, 150 mM NaCl, 1 mM EDTA, 1% Triton
X-100, 2.5 mM sodium pyrophosphate, 1 mM -glycerol-
phosphate, and protease inhibitor cocktail, Boehringer
Mannheim, GmbH, Germany) for 30 min at 4°C. Cell ly-
sates were further disrupted and homogenized by passage
through a 21-gauge needle and sonication. Cellular debris
was pelleted by centrifugation and supernatants were col-
lected and frozen at 80°C. A total of 80 g of protein (the
protein concentration was determined with BCA assay kit,
Pierce, Rockford, IL) was loaded in each well and resolved
by 10 (for pocket protein) or 15% (for all other proteins)
SDS–PAGE, followed by semidry transfer (Pharmacia, Pis-
cataway, NJ) onto Hybond-P membranes (Amersham). Af-
ter being blocked in Blotto–Tween 20 (10 mM Tris, 0.9%
NaCl, 0.1% Tween 20, and 5% nonfat dry milk) at room
temperature for 1 h, the membranes were probed with
monoclonal antibodies: anti-p21Cip (1:1000), anti-p27Kip1
(1:2000), anti-p15Ink4b (1:1000), anti-p16Ink4a (1:1000), an-
ti-cyclin E (1:1000), anti-cyclin D1/D2/D3 (1:1000), anti-
pRb (1:1000), and rabbit polyclonal antibodies: anti-Cdk4
(1:2000), anti-Cdk2 (1:2000), anti--actin (1:500). Anti-
body–antigen interaction was detected by incubation with
HRP-conjugated anti-mouse or anti-rabbit IgG secondary
antibodies and subsequently developed by using the en-
hanced chemiluminescence kit (ECL-Plus, Amersham).
Kinase assay
A total of 2  106 PBMC were treated with 2 g/ml of
6H-core or 6H-DHFR for 48 and 72 h and were simulta-
neously stimulated with anti-CD3/CD28 antibodies (1 g/
ml). Cell lysates were prepared by resuspending cell pellets
in lysis buffer as described above. Equal amounts of total
protein (80 g) from the supernatants were used for immu-
noprecipitation with anti-Cdk2 antibodies and protein A/G-
agarose (Santa Cruz Biotechnology, Santa Cruz, CA) for 1 h
at 4°C with rotation. After centrifugation, the complexes
were washed twice each in PBS and once in kinase buffer
containing 50 mM Hepes (pH 7.5), 1 mM DTT, 2.5 mM
EDTA, 10 mM MgCl2, 20 M ATP, 10 Ci [-32P]ATP,
and 10 g histone H1 (Sigma) as substrate for 30 min at
30°C. The reaction was stopped by addition of 5  SDS
sample buffer, giving a final concentration of 60 mM Tris–
HCl (pH 6.8), 10% glycerol, 2% SDS, and 5% -mercap-
toethanol. After denaturation, samples were subjected to
SDS–PAGE and specific bands were analyzed and quanti-
fied by using a phosphorimager (Molecular Dynamics).
p27Kip1 biosynthesis and stability assay
After 48 h Con A stimulation, 30  106 PBMC were
washed twice in methionine-free RPMI 1640 at room tem-
perature and incubated 1 h at a concentration of 10  106
cells/ml in 6-well plates. The supernatant was aspirated and
the cells were then labeled for 6 h at 37°C in medium
containing 0.2 mCi of [35S]Met (Redivue Promix; Amer-
sham) and IL-2 (100 U/ml), in the presence of 2 g/ml
6H-core or 6H-DHFR followed by washing. Cells were
chased for 24 h in medium containing IL-2 (100 U/ml) and
core (2 g/ml) or DHFR protein (2 g/ml). Aliquots of cells
(pulse and chase) were harvested and washed in ice-cold
PBS. Cell lysates were prepared as described above. A total
of 500 g of labeled protein extract was subjected to im-
munoprecipitation with monoclonal anti-p27Kip1 bound to
protein A/G-agarose (Santa Cruz Biotechnology), according
to the manufacturer’s instructions. The immunoprecipitated
proteins were separated by 15% SDS–PAGE. The gel was
dried at 80°C for 2 h and exposed to X-ray film (Kodak) at
80°C.
RT-PCR for Tob
A total of 1  106 PBMC were activated with anti-CD3/
CD28 antibodies (1 g/ml) and treated with 6H-core or
6H-DHFR (2 g/ml) for 6 h. Total RNA was isolated by the
TRIzol method (Life Technologies). A total of 1 g of RNA
was DNase-treated to prevent amplification of genomic
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DNA and subsequently exposed to MuLV-derived reverse
transcriptase. -Actin cDNA level from each sample was
used to normalize the samples for differences in PCR effi-
ciency. Tob mRNA quantity was determined by using end-
point dilution PCR, involving three serial 1 to 5 dilutions
(1:1, 1:5, 1:25, and 1:125) of reverse transcription (RT)
products for PCR amplification. Cycle conditions included
an initial 2 min denaturation at 95°C and final 10-min
extension at 72°C. Intervening temperatures included 30 s at
95°C, 30 s at 58°C, and 30 s at 72°C, for a total of 40 cycles.
To control for genomic DNA contamination, equal amounts
of cDNA from each sample were PCR amplified, without
RT. The resulting PCR products were separated on a 2%
BioGel (Bio 101, Carlsbad, CA). The following sets
of primers were used in the PCR reaction: Tob sense:
5-GACCCATTTGAGGTTTCTTACC-3; antisense: 5-
CCATACAGAGAGTGCATTGAGG-3; -actin sense:
5-CGAGCGGGAAATCGTGCGTGACATTAAGGA-3;
antisense: 5-CGTCATACTCCTGCTTGCTGATCCACA-
TCT-3.
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